Alpine Immune Sciences Inc
ALPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.46B
Close$
$37.58
42.2% downside
Current Fair Value
42.2% downsideOvervalued by 42.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.46 Billion |
|---|---|
| Enterprise Value | $4.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.64 |
| Beta | 0.97 |
| Outstanding Shares | 64,033,018 |
Return
| Return on Equity | -11.07% |
|---|---|
| Return on Assets | -9.86% |
| Return on Invested Capital | -13.47% |
Valuation & Multiples
| P/E Ratio | -100.94 |
|---|---|
| PEG | -160.87 |
| Price to Sales | - |
| Price to Book Ratio | 12.99 |
| Enterprise Value to Revenue | 78.62 |
| Enterprise Value to EBIT | -96.6 |
| Enterprise Value to Net Income | -121 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alpine Immune Sciences Inc
CEO: Mitchell Gold